An Emerging Role for Anti-inflammatory Agents for Chemoprevention

  • Andrew T. Chan
  • Elmar Detering
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 191)


There have been a number of promising recent developments in the prevention of colorectal cancer. This book examines in detail important aspects of the current status of and future prospects for chemoprevention of colorectal tumors, particularly using anti-inflammatory drugs. Research into the mechanisms that lead from early colorectal adenoma to colorectal cancer is discussed. The role and modes of action of available anti-inflammatory drugs, such as aspirin, celecoxib, and sulindac are described and recent data from trials of aspirin are reviewed. In addition, the possible impact of nutritional agents with anti-inflammatory properties is considered, and strategies applicable in those with a high level of genetic risk are evaluated. An important feature of the book is its interdisciplinary perspective, offering highly relevant information for gastroenterologists, internists, general practitioners, oncologists, colorectal and gastroenterological surgeons, and public health practitioners.


Familial Adenomatous Polyposis Fecal Occult Blood Testing Colorectal Adenoma Adenomatous Polyp Chemopreventive Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J et al (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885–895CrossRefPubMedGoogle Scholar
  2. Avivi D, Moshkowitz M, Detering E, Arber N (2012) The role of low-dose aspirin in the prevention of colorectal cancer. Expert Opin Ther Targets PMID 22313430 1:s51−s62CrossRefGoogle Scholar
  3. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348(10):891–899CrossRefPubMedGoogle Scholar
  4. Benamouzig R, Deyra J, Martin A, Girard B, Jullian E, Piednoir B et al (2003) Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125(2):328–336CrossRefPubMedGoogle Scholar
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884CrossRefPubMedGoogle Scholar
  6. Burn J, Bishop DT, Chapman PD et al (2011a) A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res (Phila) 4(5):655–665CrossRefGoogle Scholar
  7. Burn J, Gerdes AM, CAPP2 investigators (2011b) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378(9809):2081–2087. CrossRefPubMedGoogle Scholar
  8. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS (2005) Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294(8):914–923CrossRefPubMedGoogle Scholar
  9. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131–2142CrossRefPubMedGoogle Scholar
  10. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Wu K, Fuchs CS (2008) Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134(1):21–28CrossRefPubMedGoogle Scholar
  11. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302(6):649–658CrossRefPubMedGoogle Scholar
  12. Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM (2012) The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for the prevention of colorectal adenoma. Cancer Prev Res PMID: 22313430 5(1):61–72CrossRefGoogle Scholar
  13. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266CrossRefPubMedGoogle Scholar
  14. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313–1316CrossRefPubMedGoogle Scholar
  15. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].Lyon, France: International Agency for Research on Cancer; 2010. Available from:, accessed on 02/02/2011
  16. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E et al (2003) Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 48:1998–2002CrossRefPubMedGoogle Scholar
  17. Logan RFA, Grainge MJ, Shepherd VC, Armitage NC, Muir KR (2008) Group uT. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 134(1):29–38CrossRefPubMedGoogle Scholar
  18. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP et al (2012) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. The Lancet PMID 22440694 376(9754):1741–1750 CrossRefGoogle Scholar
  19. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377(9759):31–41CrossRefPubMedGoogle Scholar
  20. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R et al (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348(10):883–890CrossRefPubMedGoogle Scholar
  21. Schror K (2009) Acetylsalicyclic acid. Blackwell, GermanyGoogle Scholar
  22. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946–1952CrossRefPubMedGoogle Scholar
  23. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231(25):232–235PubMedGoogle Scholar
  24. Vane JR (1982) Adventures and excursions in bioassay: the stepping stones to prostaglandins. Nobel lecture, 8 December PMID 6360277Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Division of Gastroenterology Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  2. 2.Global Medical Affairs (Primary Care)Bayer Pharma AGBerlinGermany

Personalised recommendations